A phase 3 diagnostic trial evaluating 764 men with intermediate to high-risk prostate cancer found that among the 277 patients who underwent RP with lymph node dissection, the sensitivity and specificity of PSMA PET for detecting pelvic nodal metastases were 40% and 95%, respectively, thus demonstrating its high specificity for nodal staging pre-operatively [22]. This evidence concerns the gene FOLH1 and prostate carcinoma.